parents need to know about

Cord Lining banking

迎接上天恩賜的無價寶，

How will you welcome the arrival of nature’s most precious gift?

臍帶膜儲存篇101 things

您準備什麼厚禮回報 ?

Are You Ready?

Dear Expectant Parent,

You may already know that your baby’s cord blood is a source of hope; with rich haematopoietic stem cells (HSC) that may one day save the lives of your loved ones. Along with cord blood banking, now you have the opportunity to complete your child’s health protection plan by banking his/her cord lining.

While HSC from cord blood are useful for the treatment of blood related disorders such as leukaemia, lymphoma and potentially as regenerative medicine for cerebral palsy amongst other diseases, cord lining contains unique and powerful stem cells such as Epithelial stem cells (EpSC) and Mesenchymal stem cells (MSC) which may help to treat more common lifestyle and aging related diseases such as various ocular surface disorder, stroke and heart attack. More details on the potential of EpSC and MSC can be found in this educational booklet.

We understand that banking cord blood and cord lining is a personal decision that should be made with a full understanding of the current and future lifesaving possibilities. Hence, we have put together accurate and evidence-based information on cord blood and cord lining stem cells for you. We hope this will help you make an informed decision on this once-in-a-lifetime opportunity.

Just like the parent and child bond, we at Cordlife, are with you for the long haul. Having been entrusted by tens of thousands of families across Asia, we are confident that we have the right expertise and experience to help you take care of your baby’s precious medical resource. At the end of the day, we are here to give hope and save lives.

We look forward to you joining the Cordlife community.

Congratulations! This must be an exciting time for you as you await the arrival of your baby. With your pregnancy coming to a close, I am glad that you consider cord blood and cord lining banking as some of the essential preparations for your child.

With you always,Dr Jennifer TeoMedical Director Cordlife (Hong Kong) Limited

您，準備好了嗎 ?

與您攜手向前，張玉珠醫生醫務總監康盛人生 ( 香港 ) 有限公司

恭喜您！正在期待小寶寶出生的您，心情一定十分興奮。臨盤在即，為寶寶一生作一個最佳準備：保存臍帶膜幹細胞，是您最明智的決定。

也許您已經知道臍血的重要性。這蘊含豐富造血幹細胞的希望之源，將來可能會成為您孩子的救命匙。除儲存臍血外，您現在可以儲存寶寶的臍帶膜為孩子提供全面的健康保障。

臍血中的造血幹細胞於協助治療血液相關的疾病 ( 如白血病及淋巴瘤 ) 有顯著的功效，近年更被發現其潛在用途作為再生藥物治療腦痲痺減低併發症。臍帶膜中含有獨特巨大潛能的幹細胞如上皮幹細胞及間質幹細胞。兩種幹細胞均可協助治療生活中常見與年齡相關的疾病如角膜混濁或潰瘍、中風及心臟病。您可在此小冊子內找到更多有關上皮及間質幹細胞的潛在醫療價值。

我們絕對明白各位準父母決定儲存臍血及臍帶膜幹細胞前，需要對它們現時及未來的醫療效用有充分了解。因此特意為您準備這本小冊子，裡面詳列一切有關臍血及臍帶膜幹細胞的正確資料，並提供相關科學證據作參考，相信定能令您安心抉擇，把握這個一生只有一次的寶貴機會。

孩子和父母的聯繫不可分割，康盛人生也將與您並肩同行。我們的服務專業完備，在亞洲各地深受數以萬計的家庭信賴。我們具備卓越的人才和豐富的經驗，定能為您寶寶妥善儲存幹細胞，在有需要時給予希望，挽救生命。

熱切期待您加入康盛人生的大家庭。

致各準父母：

Quick Facts臍帶膜快覽

About Cord Lining

Quick Facts About Cord Lining臍帶膜快覽We have put together accurate and evidence-based information on cord lining stem cells in this booklet. By the end of this educational booklet, you will understand that:我們總括所有一切有關臍帶膜幹細胞的正確資料，並提供相關科學證據作參考。閱讀此小冊子後，您將會了解：

* in clinical trials / 臨床研究

Cord lining stem cells have immune-modulating characteristics. Therefore matching of stem cells between donor and the patient may not be required, which makes them useful both for your baby and other members in the family; 臍帶膜幹細胞擁有調節免疫系統的特性，所以捐贈者及接受移植病患的幹細胞配對是無須完全脗合便可進行移植。這有效地保障您寶寶和其他家庭成員；

With cord lining stem cells, your baby and family members will have more treatment options in the future, especially for disorders* that are incurable today such as stroke and heart attack; 臍帶膜幹細胞為您寶寶及家中其他家庭成員於未來提供更多醫療保障，特別是直至現時仍無法治癒的病症* 如中風和心臟病；

Cord lining stem cells can help to increase the success rate of a cord blood transplant; 臍帶膜幹細胞能提高臍血移植的成功率；

Cord lining contains two types of powerful stem cells as opposed to one type from Wharton’s Jelly, another part of the umbilical cord; 臍帶膜比華通氏啫喱（臍帶另一部份）蘊含多一種強效的幹細胞；

When you store cord lining for your baby and family, you are storing the original source of stem cells, which can be used to support multiple medical treatments whenever needed; 當您為寶寶及家人儲存臍帶膜，亦是儲存幹細胞的源頭。這讓您日後能取得更多幹細胞作多項醫療用途；

Compared to other sources such as bone marrow and adipose tissue , stem cells from cord lining are younger with better expansion capacity and patients receiving such stem cells have lower risk of graft versus host disease; 與其他來源相比，如骨髓和脂肪組織，臍帶膜幹細胞較年輕能作更有效的增容。不僅如此，接受移植的患者出現免疫系統併發症的機會也較低；

Using cryogenic storage method, cord lining can remain viable for a long time. This means that the therapeutic value of cord lining stem cells are well-preserved until the need for treatment arises; 臍帶膜於低溫儲存下能作永久保存。這表示臍帶膜幹細胞的醫療價值已被安好保存直至將來作治療用途；

Your baby only has one chance in a lifetime to have his/her cord lining collected as this painless and harmless process must be done at birth. 您寶寶一生只有一次機會在分娩時去採集他 / 她的臍帶膜，採集過程完全絕無痛楚及對人體不會造成任何傷害。

1

2

3

4

5

6

7

8

1

2

What什麼是臍帶膜 ?

Is Cord Lining?

What Is Umbilical Cord? 什麼是臍帶 ?

Umbilical cord is the connecting cord from the developing embryo or foetus to the placenta which allows blood to carry oxygen and nutrition to the baby in the womb. After the baby is delivered, the umbilical cord is cut and normally discarded with the placenta as medical waste until researchers became aware of its medical potential.

臍帶是連接胎盤和胎兒的管道，通過血液輸送氧氣和營養到子宮裡的胎兒。臍帶會在分娩後被剪掉，一般跟胎盤一併當作醫療癈物丟棄。直至近年，研究人員開始意識到臍帶寶貴的醫療潛力。

What Is Cord Lining?什麼是臍帶膜 ?

Other than containing cord blood, umbilical cord is composed of Wharton’s jelly, umbilical arteries and an umbilical vein. These components are protected by a sheet-like membrane known as cord lining. While Wharton’s jelly contains one type of stem cells - Mesenchymal Stem Cells (MSC), cord lining contains two important types of stem cells including MSC and Epithelial Stem Cells (EpSC).

除了含有臍血，臍帶內還有華通氏啫喱、動脈及靜脈。以上部份均被一層如紙般薄的薄膜保護，被稱為臍帶膜。臍帶內華通氏啫喱只含有一種類型的幹細胞；間質幹細胞。相對地，臍帶膜含有兩種強效類型的幹細胞：間質幹細胞及上皮幹細胞。

What Is Cellular Therapy And Regenerative Medicine? 什麼是細胞療法及 再生醫學 ?

Cellular therapy is about using cells (e.g. stem cells) as an alternative natural source to treat diseases o r damaged t i ssues o r o rgans . Regenerative medicine is the process of repairing or regenerating damaged tissues or organs to restore or establish normal function.

細胞療法是使用細胞 ( 如幹細胞 )作為天然治療疾病的來源。再生醫學是修復或重建受損的組織或器官直至機能回復正常或重新建立。

Quick Tip 小貼士

3

Cross Section Diagram Of An Umbilical Cord臍帶橫切面

Cord Lining 臍帶膜Outer protective layer of cord tissue. Contains mesenchymal stem

cells and epithelial stem cells.臍帶組織最外保護層，含有間質幹細胞及上皮幹細胞。

Umbilical Vein 靜脈

Wharton's Jelly 華通氏啫喱A homogeneous jelly like substance. Contains mesenchymal stem cells only.啫喱狀的黏膜，只含間質幹細胞。

Umbilical Arteries 動脈

MSC have self renewal capacity and differentiation capacity towards: 間質幹細胞有自我更新能力及可分化成以下細胞 :

　‧Bone cells 骨骼細胞　‧Cartilage cells 軟骨細胞　‧Heart cells 心臟細胞　‧Muscle cells 肌肉細胞　‧Nerve cells 神經細胞　‧Pancreatic cells 胰臟細胞　‧Fat cells 脂肪細胞

Mesenchymal Stem Cells間質幹細胞

(MSC)

EpSC are multi-potent stem cells capable of differentiating into: 上皮幹細胞是多效幹細胞，它能分化成 :

　‧Cornea lining 角膜組織　‧Skin lining 皮膚組織　‧Pancreas lining 胰臟組織　‧Liver lining 肝臟組織　‧ Insulin producing cells 製造胰島素的細胞

Epithelial Stem Cells上皮幹細胞

(EpSC)

What什麼是臍帶膜 ?

Is Cord Lining?

4

We would recommend you to store both cord blood and cord lining stem cells as you would be preserving unique biological resources that are equivalent to a ‘self-repair kit’ for your child and possibly, other family members.

Cord blood mainly contains haematopoietic stem cells (HSCs) which are powerful stem cells that can be used to regenerate healthy blood and immune systems. These cells have been successfully used to treat many life-threatening diseases, including leukemia, lymphoma and certain other cancers as well as blood disorders.

Cord lining contains unique and powerful stem cells including MSC and EpSC that may repair and heal the body in different ways than cord blood. These stem cells have demonstrated immense capability in aiding the repair of injured tissues and organs as well as the treatment of various diseases. MSC are building blocks of structural tissues of our body such as bone, cartilage and muscle. Cells derived from EpSC form many parts of our body including skin, hair, cornea, sweat glands as well as other secretor cells, sensing cells and cells that cover vital parts of our body such as liver. The unique ability of MSC and EpSC to differentiate into various cell types, makes them promising for cellular therapies and regenerative medicine.

為提供您孩子及其他家庭成員一個獨一無二的“自體修補儲備”，我們建議您同時儲存臍血及臍帶膜幹細胞。

臍血當中以造血幹細胞為主。這強效的幹細胞可用於重新製造健康的血液及免疫系統。它已被證實能成功用於協助治療很多可危害生命的疾病，包括白血病、淋巴瘤及多種血液相關癌症。

臍帶膜含有多種獨特及強效的幹細胞包括間質幹細胞及上皮幹細胞。它們與臍血一樣可以修復及治癒身體，各具不同功能。這些幹細胞已被證實具有巨大潛能幫助修復受損的組織或器官及治療各種疾病。間質幹細胞是結構性組織的構成原素，如骨骼、軟骨及肌肉等。上皮幹細胞構成身體各部份如皮膚、頭髮、角膜、分泌細胞包括汗腺、感官細胞及覆蓋身體主要器官的細胞包括肝臟及神經等。間質幹細胞及上皮幹細胞獨有能力可分化成多種細胞，對細胞療法及再生醫學的發展帶來希望。

Do I Need To Store Both Cord Blood And Cord Lining Stem Cells?我需要為寶寶同時儲存臍血和臍帶膜幹細胞嗎 ?

Why Should You Store Both Cord Blood And Cord Lining Stem Cells? 為何您需要同時儲存臍血及臍帶幹細胞 ?

By storing a combination of HSCs, MSC and EpSC, you are giving your child and your family more medical options in the future. Collected at birth, these cells are the youngest and most potent adult stem cells available. Most importantly, they cannot be replaced by each other.

當您同時儲存 3 種各具不同功能的幹細胞：造血幹細胞、上皮幹細胞和間質幹細胞，能為寶寶和家人將來帶來更多醫療選擇。這些最年輕和最有治療效用的成體幹細胞，僅能在寶寶出生時收集而且不能互相替代。

Quick Tip 小貼士

Why為何要儲存臍帶膜 ?

Bank Cord Lining?

5

Disorders investigated in MSC Clinical Trials 間質幹細胞應用於各種疾病的臨床研究

(more than 300 trials currently)（至今已超過 300 項）

Disorders investigated in EpSC Clinical Trials上皮幹細胞應用於各種疾病的臨床研究

Tissue repair 修復組織　‧ Stroke

中風　‧ Heart failure

心臟衰竭　‧ Alzheimer's disease

腦退化症（前稱老人痴呆症）　‧ Parkinson's disease

柏金遜症　‧ Spinal cord injury

脊髓損傷　‧ Orthopaedic indications (bone, cartilage, tendon repair)

骨科治療 （骨骼、軟骨、修補筋腱）　‧ Liver failure

肝臟衰竭Immune modulation or reconstitution 免疫系統調節或重建　‧ HIV

人類免疫缺陷病毒　‧ Type 1 diabetes

一型糖尿病　‧ Graft versus host disease (GvHD)

抗宿主疾病HSC engraftment support 輔助植入造血幹細胞　‧ Shorten time of engraftment

加快幹細胞植入時間　‧ Reduce immune system complications

減少免疫系統併發症

Soft tissue repair 修復軟組織　‧ Skin wounds

皮膚傷口　‧ Ocular surface disorders

眼部表層肌肉衰竭　‧ Persistent epithelial defect

永久上皮缺損 　‧ Replacement of insulin-producing cells for diabetic patients

為糖尿病病人更換新的製造胰島素的細胞　‧ Haemophilia

血友病

Source/資料來源 : *www.clinicaltrials.gov – search term “mesenchymal stem cells”, last assessed October 2013.

Potential Application Of MSC And EpSC In Clinic Trials 間質幹細胞及上皮幹細胞在臨床研究的潛在治療應用MSC and EpSC are currently being evaluated in more than 300 clinical trials for the treatment of medical conditions that have limited treatment options today including heart disease, stroke, spinal cord injury, cornea repair as well as wound healing such as burns and diabetic ulcers. The table outlines some of the potential applications with MSC and EpSC. As clinical research continues to take place globally, this list will continue to grow with time.

這些細胞已被採用於超過 300 項臨床試驗於多種直至現時為止無法治癒的疾病包括心臟病、中風、脊髓損傷、修補傷口 / 軟組織如角膜、燒傷或糖尿病潰瘍。下表列出間質幹細胞及上皮幹細胞的潛在治療應用，鑑於越來越多不同國家的大學或研究機構加入進行這些幹細胞對不同疾病的臨床研究，可見未來將有更多疾病出現在下表：

Why為何要儲存臍帶膜 ?

Bank Cord Lining?

6

Comparison Of MSC And EpSC Sources 間質幹細胞和上皮幹細胞的來源比較

Although MSC and EpSC can be obtained from other sources, there are many benefits of using these cells obtained from cord lining. Furthermore, other than Cordlife, all of the cord blood banks in Hong Kong can only harvest MSC from Wharton’s jelly. The table below illustrates some of the many benefits of stem cells obtained from cord lining compared to other sources.

雖然可從不同來源採集間質幹細胞和上皮幹細胞，但從臍帶膜中採集為更佳。此外，除了康盛人生以外，本港其他臍血庫只可從臍帶華通氏啫喱採集間質幹細胞。您可從下表了解從臍帶膜中採集幹細胞較其他來源更佳之處；

Parameter影響因素

Bone Marrow

骨髓

Fat脂肪

Placenta胎盤

Umbilical cord Wharton's Jelly臍帶華通氏啫喱

Cord Lining臍帶膜

Invasiveness入侵性採集 Yes 是 Yes 是 No 否 No 否 No 否

Ease of processing易於培殖 No 否 No 否 No 否 No 否 Yes 是

High yield高細胞採集量 No 否 No 否 No 否 No 否 Yes 是

MSC population是否含有間質幹細胞 Yes 是 Yes 是 Yes 是 Yes 是 Yes 是

EpSC population是否含有上皮幹細胞 No 否 No 否 Yes 是 No 否 Yes 是

Age of stem cells幹細胞原始性 Adult

較老及低原始性

Adult較老及

低原始性

Mixed (comprise cells from mother and child)混合（由母親及孩子

細胞組成）

Infant較年青及高原始

性

Infant較年青及高原始性

Presence of HLA-E/HLA-G*含有 HLA-E/HLA-G能提供免疫抑制效應 *

No 否 No 否 Yes 是 Yes 是 Yes 是

Why為何要儲存臍帶膜 ?

Bank Cord Lining?

Can MSC Differentiate To Become Epithelial Stem Cells (EpSC)? 間質幹細胞能否分化出上皮幹細胞 ?

Although there is evidence that MSC can change to certain types of EC (not stem cells), these cells cannot be changed into Epithelial Stem Cells (EpSC). The difference between EpSC and EC is that EpSC can differentiate into all different EC types such as skin, cornea, lining of the gut, etc. on demand. Whereas ECs have already reached terminal differentiation so these cells cannot be further differentiated into other EC types when needed. Thus, MSC and EpSC cannot be replaced by each other.

雖然有證據顯示間質幹細胞可分化成某些上皮細胞（非幹細胞），但間質幹細胞絕不可能轉化成上皮幹細胞。上皮幹細胞和上皮細胞的分別，在於上皮幹細胞可因應不同需要分化成特定的上皮細胞，如：皮膚、角膜、腸的軟組織等，每一種上皮細胞均是從上皮幹細胞經特定的終極轉化過程而形成，沒有能力再進一步按需要轉化成其他上皮細胞。因此，間質幹細胞和上皮幹細胞是不可互相替代的。

Quick Tip 小貼士

7

Mesenchymal Stem Cells (MSC)關於間質幹細胞

Background

More than 300 clinical trials are ongoing worldwide to uncover the medical potential of MSC. Thus far, encouraging results have been published; stem cell treatments have thus far been proven safe and indicated to be capable of repairing damage caused by stroke and heart disease. MSC have also been used in combination with HSCs as a dual therapy to promote faster engraftment of HSCs and to reduce immune system complications.

全球陸續已有超過 300 項臨床研究發掘間質幹細胞的潛力，至今各試驗結果均令人鼓舞。幹細胞療法已被證實安全及有效修復由中風及心臟病造成的損傷。間質幹細胞也可結合造血幹細胞進行治療，幫助加快造血幹細胞植入，並減少移植時出現免疫系統併發症。

‧ Under induction, able to divide to form bone, cartilage, muscle, fat and other tissues such as neural tissue, pancreatic tissue under induction經誘導下，能分化成骨骼、軟骨、肌肉、脂肪及其他的組織，如神經組織及胰腺組織

‧ Home to site of injury and assist in repair自動尋找患處並協助修復

‧ Enhance anti-infl ammatory and immunosuppression.有效消炎和免疫抑制

Background Of Mesenchymal Stem Cells (MSC)關於間質幹細胞

MSC are multi-potent cells that have displayed the following abilities: 間質幹細胞為多潛能細胞，具有以下能力：

8

Mesenchymal Stem Cells (MSC)關於間質幹細胞

Background

Source/資料來源: *parentsguidecordblood.org. Last accessed October 2013.

Definitions 定義‧Autologous is defined as derived or transferred from the same individual's body. 自體移植定義為幹細胞採集及傳輸均來自同一人體‧Allogeneic is defined as derived or transferred from another individual's body. 異體移植定義為幹細胞採集及傳輸自不同人體‧Ex-vivo is defined as in an artificial environment outside the living organism. 體外增容定義為於活生物體外的人造環境下進行增容

MSC Therapy Milestones 間質幹細胞療法的里程碑

Year年份

Indications里程碑

Remarks備註

Reference參考資料

1995 Safety證實安全

Human clinical trial phase I for ex-vivo expanded MSC. MSC infusion into human is indicated safe.第一期人體臨床研究於體外增容間質幹細胞。人體植入間質幹細胞治療顯示安全。

Lazarus et al.

1996 Bone cysts骨囊腫

Bone marrow aspirate injection to bone, 100% healing observed.骨髓注入骨骼中，損傷部位完全癒合。

Lokiec et al.

1997 Articular cartilage關節軟骨

Genzyme’s autologous chondrocyte cell therapy product, Carticel®, was given FDA approval.Carticel®：健生美 ( 美國 ) 的自體軟骨細胞治療產品獲得美國食品及藥物區認可。

FDA & Genzyme

1998 Bone defect 骨缺損

Tibial non-union, 90% healing after 6-8 months after injection of bone marrow.脛骨骨折癒合不全，注射骨髓 6-8 個月後，90% 損傷部位癒合。

Connoly et al.

2000 Hematopoietic engraftment support輔助植入造血幹細胞

Co-infusion of ex-vivo expanded MSC with blood stem cells for haematopoietic recovery. MSC infusion is feasible and safe. Indication of faster haematopoietic recovery.為輔助植入造血幹細胞，於造血幹細胞及體外增容間質幹細胞同時輸入人體。進行間質幹細胞植入治療證實可行及安全，結果顯示可加快血液疾病康復速度。

Koc et al.

2003 Amyotrophic lateral sclerosis運動神經元退化性疾病

Feasibility and safety study of ex-vivo expanded autologous MSC injection into spinal cord of patients. Therapy deemed feasible and safe.於體外增容自身間質幹細胞植入脊髓損傷患者。治療結果顯示可行及安全。

Mazzini et al

2004 Heart attack心臟病

Injection of autologous MSC from bone marrow to damaged site. Indication of improvements in MSC patient group.於一組病人體內植入間質幹細胞，該組病人經間質幹細胞治療後，病情有顯著改善。

Chen et al.

2005 Stroke中風

Infusion of ex-vivo expanded autologous MSC. Better improvements in MSC infused group than control.患病病人於體外增容間質幹細胞及進行移植。接受間質幹細胞治療組比對照組病人有更佳進展。

Bang et al.

2008 Spinal fusion脊椎融合手術

Feasibility and efficacy study of autologous enriched bone marrow MSC in combination with bone grafts. Good fusion at 34.5 months for 95.1% of the participants.研究結合骨髓間質幹細胞及骨骼移植應用的可行性和有效性。95.1% 的參與者於移植 34.5 個月後損傷部位良好融合。

Gan et al.

2010 Osteoarthritis & cartilage defects骨關節炎及軟骨損傷

Safety and surveillance study of autologous, ex-vivo expanded bone marrow MSC injection at defect sites. No tumour complications.於體外增容骨髓間質幹細胞植入到患處，進行研究安全性監測。病人證實沒出現腫瘤併發症。

Centeno et al.

2012 Acute GvHD急性抗宿主疾病

Health Canada approves Prochymal®, an allogeneic MSC therapy for acute paediatric GvHD, developed by Osiris Therapeutics Inc. Each dose of 100 million cells are now sold* at approximately US$30,000.加拿大衛生部批准 Prochymal® 上巿，此藥由 Osiris 公司採用於急性兒科抗宿主疾病研發而成的異體間質幹細胞治療藥物。每劑售價約為 US$30,000。

Health Canada & Osiris

9

Diseases 疾病 Names of Universities or Research Institutions大學或研究機構名稱

Stroke 中風

‧ University Hospital, Grenoble, France 法國格勒諾布爾大學醫院

Spinal Cord Injury 脊髓受損

‧ Chinese University of Hong Kong 香港中文大學

‧ Cairo University, Egypt 埃及開羅大學

Multiple Sclerosis 多發性硬化症

‧ Spain-Carlos Health Institute 西班牙卡洛斯健康研究所

‧ University of Cambridge, United Kingdom 英國劍橋大學

‧ Cleveland Clinic, United States 美國克里夫蘭醫療中心

Amyotrophic Lateral Sclerosis肌肉萎縮性側索硬化症

‧ Hadassah Medical Organization, Israel 以色列哈達薩醫療機構

Parkinson's Disease柏金遜症

‧ Jaslok Hospital and Research Centre, India 印度孟買醫院和研究中心

Multiple System Atrophy多發性系統退化症

‧ Yonsei University, South Korea 韓國延世大學

Liver Disease 肝病

‧ Cytori Therapeutics, United States 美國醫療生技公司

Diabetic Foot Ulcer糖尿病足潰瘍

‧ Third Military Medical University, China 中國人民解放軍第三軍醫大學

‧ Washington DC Veterans Medical Centre, United States 美國華盛頓退伍事務醫學中心

‧ Ruhr-University Bochum, Germany 德國波鴻爾大學

Diabetes糖尿病

‧ Fuzhou General Hospital, China 中國褔州綜合醫院

‧ Uppsala University, Sweden 瑞典烏普薩拉大學

MSC Clinical Trials – Global Institutions 間質幹細胞臨床研究－全球性機構

Mesenchymal Stem Cells (MSC)關於間質幹細胞

Background

MSC間質幹細胞應用報告

Application Reports

10

Source/資料來源: Chen SL et al. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chinese Medical Journal 2004 117(0): 1443-1448.

MSC and Skeletal Repair 間質幹細胞及骨骼修復‧ Treatment for knee cartilage damage was conducted by NUH Orthopaedic Surgery of Singapore, Dr Kevin Lee;　膝頭軟骨受損治療 ; 由新加坡國立大學醫院骨科手術室李凱文醫生主導研究 ;‧ Since 2006, 35 patients with worn knee cartilage underwent injection of autologous ex-vivo expanded MSC from bone marrow;　至2006年，已有35名膝頭軟骨退化患者接受自體體外增容骨髓間質幹細胞移植;‧ Patients were reported to have improvements in quality of life such as regaining ability to climb stairs and reduction of pain.　據報導，患者恢復爬樓梯能力，並減少疼痛，改善生活質素。

MSC Application Reports間質幹細胞應用報告

Source/資料來源: The Straits Times, Singapore – August 2009

Co-Transplantation of MSC and HSCs 聯用間質幹細胞及造血幹細胞移植‧ In 2002, Sydney Scott was diagnosed with Acute Myeloid Leukaemia at 13 weeks;　2002 年，小悉尼於 13 週大時證實患上急性骨髓性白血病；‧ Baby Sydney was treated with chemotherapy followed by cord blood and MSC co-transplantation – World’s First;　 在接受化療後，醫生聯用臍血的造血幹細胞和間質幹細胞植入病人體內。

這項手術讓小悉尼成為世界上第一位接受臍血：造血幹細胞兼間質幹細胞的治療；‧ MSC thought to have enabled HSC engraftment;　結果顯示間質幹細胞能加快造血幹細胞植入時間的可能性；‧ Baby Sydney was relapse free and medication free at the time of report. 　小悉尼於移植後沒有病發及毋須再服用藥物。

Source/資料來源: University of Minnesota, Paediatric Blood and Marrow Transplant Center

10

MSC in Heart Attack 間質幹細胞應用於心臟病‧69 heart attack patients were treated;　69 名心臟病患者接受治療 ;‧ Following angioplasty, doctor directly injected patients' damaged heart site with MSC harvested from

patients’ own bone marrow;先進行血管成形術，從骨髓取得自體間質幹細胞，進行培植，然後注射到受損心臟組織；

‧ Results showed signifi cant improvements in patients’ left ventricular function.　結果顯示患者左心房功能有顯著改善。

圖中受損及壞死心臟組織顯示為紫色

心臟動脈內血塊沈積阻礙血液及氧氣運送達心臟

關於上皮幹細胞Epithelial Stem Cells (EpSC) Background

Diseases疾病

Names of Universities or Research Institutions大學或研究機構名稱

Skin wound皮膚傷口

‧ Singapore General Hospital Burn Centre新加坡中央醫院燒傷中心

Ocular surface disorders眼部表層肌肉衰竭

‧ Singapore Eye Research Institute新加坡眼部研究協會

‧ Kyoto Prefectural University of Medicine, Japan日本京都府立醫科大學

Persistent epithelial defect持續性上皮缺損

‧ National Eye Institute, Hanoi, Vietnam越南河內國立眼部協會

EpSC Clinical Trials – Global Institutions上皮幹細胞臨床研究－全球性機構

11

Background Of Epithelial Stem Cells (EpSC) 關於上皮幹細胞

EpSC are pluripotent and have the capability of being differentiated into all different epithelial cell types. EpSC are considered a key resource for epidermal and skin regeneration as they have demonstrated the potential in the treatment of skin wounds, ocular surface disorders and eyes with persistent epithelial defect.

上皮幹細胞為多功能幹細胞及可分化成不同的上皮細胞。研究顯示上皮幹細胞能修復皮膚傷口、眼部表層肌肉衰竭及眼部上皮細胞永久缺損。因此上皮幹細胞已被視為修復表皮和皮膚的主要來源。

EpSC Application Reports關於上皮幹細胞應用報告

EpSC and Wound Healing 上皮幹細胞及傷口痊癒‧ Treatment trial was conducted by Singapore General Hospital, Burn Centre;

由新加坡中央醫院燒傷中心進行試驗治療；‧ 8 patients with 10 skin wounds were treated with autologous and allogenic skin epithelium (keratinocytes) cultured

and transplanted with polymer dressing aid; 8名患者身上共有10處皮膚傷口，將從自體和異體培植出來的上皮細胞（角朊細胞）利用聚合物敷料的輔助移植到傷口；

‧ Rapid re-epithelialization, closure and healing of wounds were observed.患者損傷部位達到急速表皮移植再生、傷口縫合及癒合。Source/資料來源: Tay AG et al. Cultured subconfl uent keratinocytes on wound polymer dressings in the treatment of burns and chronic wounds. Wounds 2000 12(5):127-133.

Source/資料來源: Tan DT et al. Reconstruction of the ocular surface by transplantation of a serum-free derived cultivated conjunctival epithelial equivalent. Transplantation 2004 77(11): 1729-1734.

EpSC and Ocular Surface Disorders 上皮幹細胞及眼部表層肌肉衰竭‧ Treatment trial was conducted by Singapore Eye Research Centre;

由新加坡眼部研究協會進行試驗治療；‧ 7 patients in Singapore with various ocular surface disorders received treatment;

7名新加坡眼部表層肌肉衰竭患者接受治療；‧ Autologous harvesting and cultivation of conjunctival epithelial stem cells were used;

使用了自體培植的結膜上皮幹細胞；‧ Transplantation of cultured stem cells on human amniotic membrane;

將以人類羊膜為培植基底的上皮幹細胞，移植入患者眼部；‧ All patients fully recovered: disease resolution and complication free.

全體患者完全康復：疾病痊癒及沒有併發症

EpSC and Persistent Epithelial Defect 上皮幹細胞及持續性上皮缺損‧ Treatment trial was conducted by National Eye Institute, Hanoi, Vietnam;

由越南河內國立眼部協會進行試驗治療；‧ Cord lining EpSC were transplanted in 31 eyes with persistent epithelial defect

於31對患有持續性上皮缺損的眼睛進行臍帶膜上皮幹細胞移植；‧ 29 out of 31 eyes (93.5%) healed with a single EpSC transplant;

其中29名患者(93.5%)只接受一次上皮幹細胞移植後便痊癒；‧ Normal corneal healing was observed in all 29 cases with 3-27 months follow-up.

3-27月後，此29名患者的角膜顯示正常癒合；Source/資料來源: Department of Cornea and External Diseases, National Eye Institute, Hanoi, Vietnam

Cord lining EpSC were transplanted in 31 eyes with persistent epithelial defect

Normal corneal healing was observed in all 29 cases with 3-27 months follow-up.‧

‧

‧

‧

12

EpSC Application Reports上皮幹細胞應用報告

Quick Tip 小貼士

Harvesting MSC And EpSC From Cord Lining With CellOptima™使用 CellOptima™ 技術採集臍帶間質及上皮幹細胞

Patented Technology with 16 Patent Protection granted and 10 more pending 獨家專利科技：擁有16個國家發明專利授權及有10個國家授權等候審批

Available exclusively at Cordlife in Hong Kong, CellOptima™ can isolate and expand two types of stem cells; MSC and EpSC, from your baby’s cord lining.

康盛人生是本港唯一獲授權的幹細胞儲存庫提供 CellOptima™ 服務：能從您寶寶的臍帶中分離間質及上皮幹細胞。

More than 20 years ago, bone marrow was found to contain MSC subsequently Wharton’s Jelly from the umbilical cord was found to contain MSC as well. More recently, a team of award-winning doctor and scientist from Singapore made significant inroad in the world with the discovery of two powerful stem cell types, MSC and EpSC, from cord lining. Together, the Cambridge and Stanford University trained duo developed a unique technology known as CellOptima™, designed to harvest and multiply stem cells from cord lining. This revolutionary discovery led the team to receiving patent grants from 16 countries including United States, China, Singapore, Hong Kong and patent grants from another 10 countries are still pending for final approval. These patents prohibit anybody other than the patent owner from harvesting stem cells from cord lining.

20 多年前，已有研究員發現骨髓及臍帶裡的華通氏啫喱均擁有間質幹細胞。直至近年，新加坡一班獲獎的醫生及科學家團隊得出一個影響著全球幹細胞研究發展的成果：他們發現臍帶膜中擁有兩種強效幹細胞，即間質幹細胞及上皮幹細胞。這兩位於英國劍橋大學及美國史丹褔大學受訓的研究員隨即研發一項獨有技術：CellOptima™，專為培植及增容臍帶膜中的幹細胞。此項革命性的研發技術接著為團隊帶來 16 個國家的專利授權包括美國、中國、新加坡及香港，額外還有 10 個國家授權正等候審批。這些專利明確地禁止除專利擁有者以外人仕從臍帶膜中取得幹細胞。

List of Patent Protection Granted認可專利技術列表

Countries國家

Patent Number專利編號

United States 美國 US 8,287,854 B2

Great Britain 英國 GB2432166

Singapore 新加坡 129482

Hong Kong 香港 HK1104061

China 中國 1220904

Taiwan 台灣 312009

Australia 澳洲 2005273077

New Zealand 新西蘭 553695

South Korea 南韓 10-1322889

Indonesia 印尼 ID P 0023508

Malaysia 馬來西亞 MY 141772

Israel 以色列 181340

Mexico 墨西哥 282372

Russia 俄羅斯 2416638

South Africa 南非 2007/2144

Vietnam 越南 I-2007-00574

What Makes CellOptima™ Special?CellOptima™ 有什麼獨特優勢 ?

CellOptima™ is an original invention from Singapore. Patent protection of CellOptima™ has been granted by many countries because the technology is novel, first-of-its-kind and useful. All patents granted CellOptima™ prevents other companies from harvesting stem cells from cord lining.

CellOptima™ 是新加坡原創研發技術。由於此項專利技術較新穎、前所未見及證實有用，故受多個國家認可。全港只有康盛人生才可從臍帶膜中採集間質及上皮幹細胞。

13

CellOptima™康盛人生獨家突破專利科技

Cordlife Patented Technology

Focus研究焦點

Partner Universities or Research Institutions 合作大學或研究所

Heart restoration and repair心臟修復

‧National University of Singapore 新加坡國立大學‧Hamburg University, Heart Centre, Germany 德國漢堡大學心臟中心

Wound management and burns傷口處理及燒傷

‧Shriner's Children's Burns Hospital, United States 美國施瑞納兒童燒傷中心‧Chinese University of Hong Kong 香港中文大學‧National Burns Centre, Hanoi, Vietnam 越南河內國立燒傷中心

Cornea regeneration角膜再生

‧Singapore Eye Research Institute, Singapore 新加坡眼部研究協會‧National Eye Institute, Hanoi, Vietnam 越南河內國立眼部協會

Liver regeneration肝臟再生

‧National University of Singapore 新加坡國立大學

Skin & hair rejuvenation皮膚及毛髮更生

‧Camden Medical Centre, Singapore 新加坡坎登醫務中心‧BK Clinic, South Korea 韓國 BK 東洋整形外科醫院‧National Institute of Dermatology, Hanoi, Vietnam 越南河內國立皮膚醫學院

Insulin-producing cells製造胰島素的細胞

‧National Cancer Centre, Singapore 新加坡國立癌症中心‧National University of Singapore 新加坡國立大學

Neuronal differentiation for hearing impairment弱聽遺傳性變異

‧Stanford University, United States 美國史丹褔大學

Bone differentiation, repair and regeneration骨骼分化 , 修復及再生

‧AO Foundation, Switzerland 瑞士 AO 基金會‧Keele University, United Kingdom 英國基爾大學

Hemophilia AA 型血友病

‧National Cancer Centre, Singapore 新加坡國立癌症中心

Human feeder layer for stem cell culture人類滋養層用於培植幹細胞

‧ Duke University, United States and National University of Singapore (co-collaboration) 美國杜克大學及新加坡國立大學（共同研究）

List of Clinical Trials With Stem Cells Harvested With CellOptima™使用 CellOptima™ 採集幹細胞之臨床研究列表

14

CellOptima™康盛人生獨家突破專利科技

Cordlife Patented Technology

15

Optimal Condition Assurance 最佳狀態保證Using CellOptima™ proprietary cell biomarker verifi cation, your baby’s cord lining will be tested after 4 weeks of cryopreservation. During this process, sample segments of the frozen cord lining will be thawed and MSC and/or EpSC will be harvested according to your choice of storage plan. This verifi cation step is important as it helps ensure that your baby’s cord lining has been properly stored and can be used for future medical treatments. The objective of this process is to validate the following:

使用 CellOptima™ 細胞生物標記核實，您寶寶的臍帶膜樣本會於冷凍 4 星期後進行測試。過程中，臍帶膜冷凍樣本會被解凍及根據您所選擇的儲存服務計劃進行間質及/或上皮幹細胞採集。此核實步驟非常重要，它保證您寶寶的臍帶膜已被適當地儲存及可用於未來治療，通過這過程，以下特點將會被證實：

‧ Cell type/s confi rmation using MSC and/or EpSC biomarkers 以細胞生物標記核實來確認細胞種類 ‧Cell viability 細胞活性能力‧ Cell proliferation also known as the ability to multiply further 細胞增容能力也稱為繁殖能力 ‧Cord lining sterility 臍帶膜無污染測試

Explant Purity & Dual Source Storage Assurance 移植細胞純度及雙重資源儲存保證If you choose to extract stem cells now from your baby’s cord lining whether MSC, EpSC or both for long-term storage, you will automatically enjoy complimentary storage of the cord lining in its original unexpanded form. This gives your family double access to both expanded stem cells which are “treatment-ready” as well as unmanipulated cord lining that can be used for multiple treatments and possibly the extraction of other cell types not identifi ed today. In addition to CellOptima™ proprietary cell biomarker verifi cation, the tests below will be done on the expanded stem cells to ensure that they are viable and safe for use.

若您現在選擇從您寶寶的臍帶膜中進行間質幹細胞及/或上皮幹細胞增容作長期儲存，您將會自動享有免費臍帶膜原體儲存。這讓您的家人可同時擁有已增容的幹細胞作 “即時可用於治療”及未經增容的臍帶膜：輔助多種治療及可於未來有機會分化成現今尚待識別的幹細胞種類。除了使用 CellOptima™ 細胞生物標記核實，我們將於增容細胞時進行以下檢驗，確保幹細胞活性能力及安全性：

‧ Count of cells 細胞量　‧ Cell sterility testing 細胞無污染測試　‧ Endotoxin analysis 內毒素分析　‧ Mycoplasma analysis 支原體分析

Usability Assurance 可用性保證Both MSC and EpSC harvested with CellOptima™ have been used successfully in human clinical applications. This gives you peace of mind knowing that what you are storing today, can really be used in the future to help your family.

應用CellOptima™所採集及增容的間質幹細胞和上皮幹細胞已於人類臨床研究獲得成功。這讓您更清晰了解您現在所儲存的幹細胞，能於未來給您與您的家人使用。

Technology Accessibility Assurance 科技應用保證As long as you remain a cord lining client of Cordlife, you are a guaranteed member of Global Cord Registry. As a member, you will have automatic access to CellOptima™ for the isolation and expansion of MSC and/or EpSC to support medical treatments. This membership is only granted to Cordlife clients in Hong Kong.

凡於康盛人生儲存臍帶膜的客戶將會自動成為全球臍帶膜註冊處的會員。作為會員，您可透過我們應用 CellOptima™ 來採集及增容間質幹細胞及/或上皮幹細胞作醫學治療之用。在香港，此會藉只限於有關康盛人生客戶。

CellOptima™給您與您家人的信心保證

Assurances For You And Your Family

CORD LINING臍帶膜 — 儲存臍帶膜和增容後的幹細胞的比較

- Comparison of Storing Cord Lining Vs Explant Stem Cells

16

At Cordlife, you have the option to store your baby’s cord lining in its original form or in expanded stem cells form. If you choose to isolate and expand MSC or EpSC now, we will offer complimentary storage of the cord lining in its original form so that more cells can be isolated and expanded in the future.

於康盛人生，您可選擇儲存寶寶原始的臍帶膜或增容后的間質幹細胞及 / 或上皮幹細胞作長期儲存。如果您選擇即時增容服務，我們會為您免費儲存原始的臍帶膜，讓您家人日後能採集更多幹細胞。

Cord Lining 臍帶膜 Explant Stem Cells 增容后的幹細胞

Description of service服務描述

Cord lining stored in its original form with minimum manipulation以臍帶膜原體儲存：無多餘的加工處理

MSC or EpSC harvested from cord lining and stored as cell form 從臍帶膜裡採集及增容間質幹細胞或上皮幹細胞後以幹細胞形式儲存

Status狀態

Minimally manipulated therefore original characteristics and potential of stem cells contained within cord lining maintained為保存臍帶膜擁有最原始的特性和潛能， 所以不作多餘的加工處理

Identified type of stem cells isolated 分離指定幹細胞種類

Number of cryovials抗凍管數量

4 units of 3.6ml 4 支 3.6 亳升

‧ 4 units of 3.6ml with expanded MSC or EpSC 4 支 3.6 亳升已增容的間質幹細胞或上皮幹細胞

‧ Complimentary 4 units of 3.6ml with cord lining 附送 4 支 3.6 亳升的臍帶膜

Availability供應

Minimally 2 – 4 weeks for isolation and expansion depending on cell dose required. 依不同的細胞劑量需求，需時 2 至 4 個星期來增容

Immediate* if sufficient cell count is available 如有足夠的細胞數量可立即*供應

Potential to extract other types of stem cells other than MSC and EpSC採集其他幹細胞的可能性

Yes 有

No 無

* 供應取決於醫護人員進一步處理幹細胞所需時間

Quick Tip 小貼士

How Is Umbilical Cord Collected?如何收集臍帶膜 ?

Obtaining the umbilical cord is just an extension of your baby’s cord blood collection, cord lining will be collected by cutting a segment of your baby’s umbilical cord. Baby's umbilical cord is collected at the time of delivery by the obstetrician or caregiver. After your baby’s cord blood has been collected, your obstetrician or midwife will clamp and cut a segment of the umbilical cord. This cord will be stored in a sterile container provided in your Umbilical Cord Collection Kit. This process is entirely safe and painless for both mother and child.

收集臍帶是採集臍血延伸的步驟，臍帶膜從您寶寶被剪斷的臍帶中收集。寶寶的臍帶會於分娩時由醫護人員收集。分娩後，您的產科醫生或助產士會把臍帶鉗緊、剪斷。而在成功採集臍血後，部份的臍帶會被剪下，並將其存放到「臍愛盒」中指定的無菌容器內。整個過程絕對安全，對母親和寶寶均不會帶來任何痛楚。

CORD LINING臍帶膜 — 收集、處理及低溫儲存

- Collection, Processing and Cryopreservation

Steps Of Umbilical Cord Processing And Storage處理和儲存臍帶幹細胞流程

After collection, your baby’s umbilical cord will be sent to Cordlife’s facility located in Hong Kong Science Park for processing and cryopreservation. Prior to processing, the identity of the umbilical cord collected is verified by our trained medical technologist to ensure that there is no sample mix up. All subsequent steps are performed within a bioharzard safety cabinet to eliminate the risk of contamination.

成功採集後，您寶寶的臍帶會被送往康盛人生於香港科學園的實驗室進行處理及儲存。處理前，已受訓練的醫務實驗室專員首先會核對樣本身份以確保樣本不會混淆。所有步驟會於生物安全操作台進行以進一步減低樣本被污染的機會。

Next, the umbilical cord is processed, cleaned with wash buffer solution containing anti-microbial agents and segmented into small pieces.

之後，醫務實驗室人員會用含有抗微生物劑的沖洗液清洗及處理臍帶，再將臍帶切割分為細小組織。

2 31 4

17

Steps Of Umbilical Cord Processing And Storage處理和儲存臍帶幹細胞流程

The decontaminated segments are then transferred into multiple cryovials added with cryoprotectant solution to safeguard the viability of the segments during cryopreservation. Every client will have a total of 4 units of 3.6ml cryovials and 2 units of 1.8ml cryovials. The smaller cryovials are used mainly for testing purposes. By storing the segments in multiple cryovials, you have the option to withdraw one cryovial at a time without affecting the viability of segments in other cryovials.

清潔後的組織將被放入多支特製的抗凍管，加入冷凍保護劑以保障低溫冷藏狀態下組織的活性。每位客户會擁有共 4 支 3.6 毫升的抗凍管和 2支 1.8 毫升的抗凍管。這種儲存方法能讓您抽取其中一支抗凍管時也不會影響其他抗凍管組織的活性。

Once the cryoprotectant solution has been added, the segments are frozen gradually in a controlled-rate freezer, where the temperature is lowered to preserve the viability of the segments.

在加入冷凍保護劑後，抗凍管內的組織將被放入程控降溫儀，將組織進行緩速降溫，以保存幹細胞的活性。

After the controlled-rate freezing process, the cryovials will then be transferred to a MVE vapour-phase l iquid nitrogen storage system for long-term cryopreservation at approximately -190oC. This system is used and trusted by many cord blood banks in the world for decades. If you choose to extract stem cells now from your baby’s cord lining for long-term storage, the cells will be harvested from post-thawed cord lining using CellOptima™ and then finally stored long-term until the need for a treatment arises.

經緩速降溫後，抗凍管會被移送至 MVE 氣態氮儲存系統，在約攝氏零下 190 度低溫下作永久保存。這系統已被多間主要的國際臍血臍帶庫採用及信賴多年。如您選擇現在從寶寶的臍帶膜抽取幹細胞作永久保存，我們會透過CellOptima™ 技術在解凍後的臍帶採集幹細胞，作永久保存直至有需要治療。

6 75 8

CORD LINING臍帶膜 — 收集、處理及低溫儲存

- Collection, Processing and Cryopreservation

18

Cordlife康盛人生為您孩子提供保障之最

Here With You For The Long Haul

Protecting Your Baby’s Cord Lining And Stem Cells Like Our Own就像康盛人生的寶物一樣，我們致力保護您寶寶的臍帶膜及幹細胞

Headquartered in Singapore, Cordlife Hong Kong is a fully owned subsidiary of Singapore Exchange Mainboard listed company, Cordlife Group Limited. As a Group, we have accumulated more than 13 years of experience in cord blood and cord lining processing and cryopreservation. Apart from our state-of-the-art facility located in Hong Kong Science Park, Cordlife also operates facilities in Singapore, Indonesia, India and the Philippines as well as strategic investments in other cord blood banks in China and Malaysia.

集團總部位於新加坡，康盛人生（香港）附屬新加坡交易所（SGX）主板上市公司，康盛人生集團。康盛人生集團累積超過 13 年豐富處理及儲存臍血和臍帶膜的經驗。除了於香港科學園擁有先進及完善的設施，康盛人生的設施更伸延至新加坡、印尼、印度及菲律賓。本公司也在中國及馬來西亞各地投資於其他臍血庫。

Cordlife’s facility in Hong Kong is fully managed by highly qualifi ed and licensed medical biotechnologists with many years of experience. Our AABB accredited facility operates 7 days a week, 365 days a year. To ensure that all our clients’ cord blood and cord lining units are cryopreserved in optimal condition, our facility is closely monitored round-the-clock and equipped with the most advanced fi re protection system and multiple backup systems for the provision of power at all times.

康盛人生於香港的設施是由專業及累積多年經驗的醫務實驗室專員處理。我們的設施獲得美國血庫協會（AABB）國際品質認證。為提供最完善的服務，我們 365 日年中無休，全天候 24 小時運作。不僅如此，為確保我們的客戶所儲存的臍血和臍帶膜保存於最佳狀態，我們的設施每分每秒都受到嚴密的監控，而且更配備最先進的防火系統及多項後備系統以確保電源充足。

也在中國及馬來西亞各地投資於其他臍血庫。

19

5 Simple Steps選用康盛人生，只需5個簡單步驟

To Bank With Cordlife

Step 1 : Enrol With Cordlife第一步：於康盛人生登記Call our Cord Blood Banking Consultant at Hong Kong (852) 3980 2888 / Macau (853) 6233 8754 to arrange for a meeting.*If your baby is due within the next 4-6 weeks, please contact us now to ensure all necessary steps are undertaken in time for your delivery.

聯絡我們的顧問 香港 (852) 3980 2888 / 澳門 (853) 6233 8754，安排會面。* 若您將於 4 至 6 周內分娩，請立即聯絡我們，以確保所有手續能於寶寶出生前辦妥。

Step 2 : Receive Your Collection Kit第二步：領取「臍愛盒」Once the enrolment procedure is completed, we will provide you with personalized Umbilical Cord Collection Kit. The kit will contain everything needed for the collection of your baby’s Umbilical Cord.

辦妥登記手續後，我們會給予您專屬的「臍愛盒」，用來收集臍帶。

Step 3 : Inform Your O&G doctor第三步：通知主診醫生Inform your O&G doctor that you have enrolled with Cordlife for Umbilical Cord collection.

通知您的主診醫生，您已登記康盛人生臍帶膜儲存服務。

Step 4 : Bring Your Collection Kit第四步：攜帶「臍愛盒」Remember to bring your Collection Kit along with you to the hospital for delivery.

入院分娩時，謹記攜帶「臍愛盒」。

Step 5 : Call Us Upon Your Arrival At The Hospital And After The Delivery

第五步：入院及產後通知Call us at Hong Kong (852) 3980 2999 / Macau (853) 6233 8754. We will arrive within 12 hours to retrieve the Collection Kit and send the Umbilical Cord to our laboratory for processing.

抵達醫院時及分娩後，請致電 香港 (852) 3980 2999 / 澳門 (853) 6233 8754，我們將於 12 小時內到達醫院取回您的「臍愛盒」，並送往實驗室處理。

Umbilical Cord Collection Kit 臍愛盒（臍帶用）

DCR No.1208 UCT_BK_v1.5_20140420

Hong Kong 香港 : (852) 3980 2888 Macau 澳門 : (853) 6233 8754

24 HOUR HOTLINE24小時熱線

Main Offi ce and Laboratory / 香港總辦事處及實驗室Units G11-12 &15, G/F., Biotech Centre 2, No.11 Science Park West Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong香港新界沙田香港科學園科技大道西11號生物科技中心2座地下G11-12及15室Tel / 電話: (852) 3980 2980

Macau Representative Offi ce / 澳門辦事處Rua De Coelho Do Amaral, No.91 R/C Macau澳門連勝街91號廣宜居地下A舖（鏡湖醫院對面）Tel /電話: (853) 2835 2266